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abStract
Osteoporosis is considered one of the most common and 
serious problems affecting the elderly population worldwide. 
It is a chronic and progressive disease, characterized by de-
creased bone mass and degeneration of the microarchitecture 
of the bone tissue. Gene therapy represents a new approach 
in osteoporosis treatment, and its main function is to restore 
the compromised function in the metabolism. This review aims 
to elucidate the main studies on gene therapy in recent years, 
in the medical databases, that use gene therapy for the treat-
ment of osteoporosis in animal models, as well as the future 
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prospects of this therapy. The majority of the studies use the 
BMP, PTH and OPG genes, in an attempt to reestablish bone 
mass. Despite the lack of new molecules, all genes employed 
in these studies have proven to be efficient in the treatment of 
the disease. The benefits that gene therapy will provide for pa-
tients in the future should contribute substantially to increasing 
the quality of life for the elderly. Soon, clinical trials involving 
humans will benefit individuals with osteoporosis.
Keywords: Osteoporosis. Gene therapy. Orthopaedics. Ge-
netic vectors.
introDuction
Osteoporosis is considered a chronic and progressive dis-
ease, characterized by decreased bone mass and deteriora-
tion of the bone tissue microarchitecture. These changes lead 
to an increase of bone fragility and consequently, to a greater 
risk of fractures.1
Osteoporotic fractures are significant causes of functional loss 
and decrease in quality of life of the affected individual. The 
most accentuated loss of bone mass occurs in women from 
menopause, and is associated with estrogen insufficiency.2 
The most severe fracture resulting from postmenopausal os-
teoporosis is that of the femur. In a study developed by Jiang 
et al.3 in Canada, the mortality rate reached 6.3% in the first 
year and 30.8% in the second year after the fracture. This 
mortality rate is in conformity with the rest of the world, which 
varies from 1.02 to 10% during the hospital stay and from 23 
to 30% during the first year after the fracture.4
In Brazil, the census figures draw attention to the large num-
ber of elderly individuals (14 million), the population with the 
greatest risk of developing osteoporosis. Over the period of 
one year 129,611 cases of osteoporosis were diagnosed in the 
private healthcare system, with an incidence of 4.99% in femo-
ral fractures in the female population. The mean hospitalization 
time was higher than nine days and the direct cost per patient 
after hospitalization was calculated at R$ 24,000.00.5
In the city of São Paulo, a study with individuals over 65 years 
of age demonstrated that 92.8% of the women had osteope-
nia and/or osteoporosis in at least one part of the skeletal 
system analyzed.6
It is calculated that in 2050 there will be approximately 6.3 
million fractures per year, with the majority occurring in Asia 
and in Latin America.7
Most of the drugs currently used for osteoporosis treatment 
have an antiresorptive (estrogens, raloxifene, calcium and vi-
tamin D, alendronate, etidronate, risedronate and calcitonin) 
and/or anabolic (PTH 1-34 and strontium ranelate) action.8
Gene therapy has been indicated as a promising method for 
the treatment of osteometabolic diseases and represents a 
new approach in osteoporosis treatment. Gene therapy inserts 
the gene that codifies a protein which, if it were injected on its 
own, would be rapidly degraded.9,10
The basic principle of this therapy is to introduce exogenous 
genetic material to correct or modify cell function. Genetic 
material, called therapeutic gene, can be introduced into the 
target cell by genetic engineering techniques.9,11
The therapy starts with the modification of a basic structure, 
called plasmid. Plasmid is a small circular unit of DNA found 
in bacteria. Plasmid modification basically consists of the al-
teration of the expression cassette (promoter, complementary 
DNA of the therapeutic gene and a polyadenylation signal), 
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table 1. Main types of vector used in gene therapy to potentiate the 
entrance of DNA into the nucleus of the target cell.
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Types of vector
Viral Non-viral
Retrovirus Naked DNA
Adenovirus Physical:
Adeno-associated Electroporation
Herpes simplex  virus Biobalistic process
Sonoporation
Hydrodynamics
Magnetofection
Chemical:
Lipoplex
Polyplex
Biological:
Bacteria
Virosome
Ad-lipo
which has the necessary regulatory signals for the expression 
of the gene of interest. The erroneous choice of any element 
may result in failure of the therapy or even be detrimental to 
the target cell.11
After the construction of the plasmid with the specific and 
necessary sequences for its maintenance and expression, 
this structure can be transferred to the target cell with the help 
of viral (transduction) and non-viral (transfection) vectors.11,12 
It is known that for the transduction of host cells, viruses are 
effective at transmitting their genetic material. Therefore some 
groups stand out among the viral vectors, including the retro-
viruses, adenoviruses, adeno-associated viruses and herpes 
simplex virus. In transfection, the plasmid with the therapeutic 
gene can be incorporated to the target cell by physical (elec-
troporation, biobalistic process, sonoporation, hydrodynamics 
and magnetofection), chemical (lipoplex, polyplex), or biologi-
cal (infection via bacteria, virosome, Ad-lipo) methods. (Table 
1) The choice of the current vector is based on the type of di-
sease, the size of the therapeutic gene, the therapy route and 
the duration of the gene expression; these characteristics are 
important for the gene transfer to occur successfully.9,11,12
Moreover, the therapeutic gene can be delivered to the site of 
interest by the in vivo strategy, in which the gene is transferred 
directly to the site. This type of strategy has proved to be simple, 
low costing and minimally invasive. On the other hand, in the 
ex vivo strategythe transfer of the gene of interest is performed 
in the cells that were collected from the patient, followed by re 
(implantation) in the target tissue. (Figure 1) For this reason, this 
kind of approach is more meticulous and expensive.9
Each strategy has advantages and disadvantages. While in 
the in vivo strategy the material appears to be restricted to the 
injected site and to present low efficiency in transduction, in 
the ex vivo strategy this efficiency is greater, with the possibility 
of controlling viral particles and plasmids, yet this process 
lasts longer.9,11,12
This review aims to focus on the most relevant studies on 
gene therapy for osteoporosis treatment developed in recent 
years in animal models, as well as the future prospects of 
this therapy.
The methodology used was a review of literature carried out 
by electronic search in the MEDLINE/PubMed, LILACS, ISI 
-Web of Science and SciELO databases with special reference 
to the original articles involving the key words osteoporosis, 
gene therapy, viral vector, non-viral vector, adenovirus, retrovi-
rus, adeno-associated virus, lentivirus, bone morphogenetic 
protein and osteoprotegerin, using as a reference either MeSH 
(Medical Subject Headings) or DeCS (Health Sciences Des-
criptors). The inclusion criteria were studies published in the 
English, Portuguese and Spanish languages in recent years. 
The main experimental articles are expressed in Table 2 and 
some of these were cited in the text.
Physiopathology of osteoporosis
The human skeleton is constantly renewed by the joint and 
coordinated action of the osteoblasts and osteoclasts, spe-
cialized cell types, responsible for bone remodeling. The im-
balance between the formative activity of the osteoblasts and 
resorptive activity of the osteoclasts results in loss of bone 
mass and skeletal fragility, contributing to the physiopathology 
of osteoporosis.2 Parathormone (PTH) and calcitonin are the 
main regulators of calcium homeostasis and respond to the 
changes in calcemia. The reduction of calcemia induces an 
increase in PTH production, while rising values decrease its 
production. The presence of G protein-coupled type 1 PTH 
receptor (PTHR1) in the osteoblast enables the recognition of 
the amino-terminal portion of the PTH, which results in activa-
tion of the protein kinase C (PKC) routes and the protein kinase 
A route (PKA). Although the two routes are activated by PTH, 
PKA is the main route of activation,8 leading to the increase 
in the number of osteoclasts. The simplified mechanism is 
shown in Figure 2.
Unlike PTH, calcitonin acts by decreasing the level of serum 
calcium by stimulating osteoblastic activity.2
Multifactorial causes can be attributed to the triggering of os-
teoporosis, such as decrease in the ingestion or intestinal ab-
figure 1. Diagram of the delivery strategies of the therapeutic gene to the site 
of interest. In vivo transduction involves the direct transfer of the gene and ex 
vivo transduction involves the collection of the target cell; expansion in cell cul-
ture, transduction of the vector and (re)implantation at the site of interest. 
Adapted from Fischer et al.9
Direct 
transfer
Target tissue
Extraction of 
target cell
Cell culture
(Re) implantation
Vector
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Experimental studies of gene therapy for osteoporosis
Therapeutic Gene Vector Quantity Model Investigator Year
CXCR4 and Cbfa-1 MSC– mediated Adenovirus 1x10 6 cells Mice♀ Lien et al.20 2009
BMP-2 MSC– mediated  Adenovirus (Ad5F35) 2500 viral particles Mice♂ Gugala et al.24 2007
RANK-Fc MSC–mediated Retrovirus
1x107 cells per mL (total volume 
of 0.2mL/animal)
Mice♀ Kim et al.18 2006
BMP-2 Naked plasmid 25 μg Rats♂ Kawai et al.23 2005
Human β3 integrin (Mononuclear cells– mediated 
Retrovirus (Lentivirus
2x10 6 mononuclear cells Mice♀ Zhao et al.31 2005
BMP-2 MSC–mediated Adenovirus (Ad5) 1x107and 2 x107 cells per block Rats♂ Yue et al.22 2005
hOPG Adeno-associated virus (AAV-2) 5x10 9viral particles Female Rats♀ Ulrich-Vinther et al.26 2005
hPTH and RGD Naked plasmid
300 μg of RGD and100 μg of 
hPTH
Female Rats♀ Chen et al.16 2005
hOPG Adeno-associated virus (AAV-2) 6x1011viral particles Mice♀ Kostenuik et al.27 2004
Preand prep-prosequence 
of hPTH
Naked plasmid 50 μg Mice♀ Liu et al.33 2004
hPTH Nakied plasmid 50 μg Mice♀ Liu et al.17 2003
BMP-4 Adeno-associated virus (AAV-2) 2x1012viral particles Rats♂ Luk et al.21 2003
IL-1Ra Adenovirus (Ad5) 1x1010viral particles Mice♀ Baltzer et al.14 2001
BMP-2 Cells–mediated Retrovirus 5x10 6 cells Mice♂ Engstrand et al.25 2000
table 2. Main gene therapy studies conducted for osteoporosis treatment in non-human animal models in recent years.
H�N-
PTH
IL-6 e OPG-L
(osteoclastogenesis)
IGF-I, IGF-II e TGF-ß
(bone formation )
Gq
Phospholipase C 
PKC
Gs
Adenyl cyclase
PKA
figure 2. Diagramof interaction between PTH with the receptor PTHR1 
present in the osteoblasts.
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sorption of calcium and vitamin D, duration of the reproductive 
cycle, genetic factors, habits such as alcohol and tobacco, 
exercise and others.13
In spite of efforts, the physiopathological mechanisms involved 
in the osteoporosis process remain incomplete.
Gene therapy: pre-clinical studies
One of the first studies to evaluate the possibility of using a 
murine model for gene therapy for the treatment of osteoporo-
sis was developed by Baltzer et al.14 In this study the authors 
used a model of oophorectomized female mice and the ade-
novirus serotype 5 vector to perform the delivery of the hu-
man IL-1Ra gene in the medullary cavity of the femoral bone. 
The IL-1Ra gene is responsible for encoding the “interleukin-1 
receptor antagonist” protein. The biological function of this 
protein is reversed to one of the activities of the inflammatory 
cytokine IL-1 (Interleukin-1), which is a bone resorption inducer 
and is increased in postmenopausal women. In this manner, a 
protein that inhibits IL-1 activity appears to be an important tool 
in the attempt to decrease bone loss. The results showed that 
all the bones were protected against loss of bone mass, and 
not just the femur that received the injection with the vector. 
The authors reinforce the idea proposed by Oyama et al.15 
that transduced cells are capable of moving through the bone 
marrow of different bones.
Chen et al.16 also used the oophorectomized animal model to 
induce bone loss, but used female rats at an age of 56 weeks. 
After the surgical procedure the quadriceps muscle of both 
legs was transfected with the naked plasmid containing the 
PTH gene or the peptide-treated RGD encoding gene. After 
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three months the animals were sacrificed and the results sho-
wed a 10.1% increase in bone mineral density in the group that 
received the PTH gene and an 8.9% increase in the one that 
received the RGD gene. Bone loss was avoided in the animals 
that received the RGD gene, since this is an antagonist of 
some integrins responsible for cell adhesion, such as human 
β3 integrin. Therefore the osteoclasts are unable to maintain 
their adherence to the cell surface, and the resorption rate 
decreases, besides which this molecule also induces oste-
oclast apoptosis. Now in the animals that received the PTH 
encoding gene, the increase in the parameters evaluated can 
be explained by the fact that PTH exercises anabolic action 
when administered intermittently and in low doses.8
In a previous study conducted by Liu et al.17, the authors had 
already successfully performed the transfection of the quadri-
ceps muscle of female mice with PTH encoding gene. On that 
occasion they had observed that at the end of eight weeks of 
treatment the expression remained. In order to increase trans-
fection efficiency the authors used the method known as elec-
troporation. In this method an electrical discharge was applied 
using a pistol, bringing about a change in the permeability of 
the plasma membrane, which facilitated the penetration of the 
gene in the target cells.12
Many researchers use the mesenchymal stem cells (MSCs) as 
mediators for osteoporosis treatment, inducing their differentia-
tion in osteoblasts and avoiding accentuated bone loss.18,19
The first study that showed the applicability of the systemic 
transplantation of genetically manipulated and intravenously 
injected MSCs is recent. After inducing bone loss with gluco-
corticoids, the authors transduced MSCs with the adenovirus 
carrying the encoding gene of the CXCR4 or CXCR4 protein 
with Cbfa-1 in female mice, and noticed that the total recovery 
of bone mass occurred in the animals that expressed the CX-
CR4 protein while strength and hardness was recovered only 
in the group that received the two genes. The recovery of bone 
mass occurred due to the fact that the cells transduced with 
CXCR4 played a crucial role in osteogenic differentiation.20
With the aging of the individual, the number of MSCs decreas-
es, but the differentiation capacity does not change, which 
could represent a problem, since the studies use relatively 
young oophorectomized animal models in comparison with 
what occurs in type I primary osteoporosis18 (characterized by 
estrogen deficiency in postmenopausal women).
In view of the foregoing, there is an evident need for more stu-
dies focusing on the quantity of MSCs and the differentiation 
capacity during the different stages of human development, 
particularly after menopause.
Most studies in gene therapy for osteoporosis employ the gro-
wth factors known as BMPs (bone morphogenetic proteins). 
These proteins are part of the TNF-ß (tumoral necrosis factor 
ß) superfamily, and act in differentiation, proliferation and che-
motaxis, stimulating osteogenesis in animals and humans. The 
BMPs most frequently studied and employed in gene therapy 
include BMP-2 and BMP-4.21-24
Yue et al.22 showed that the quantity of MSCs diminishes with 
age, yet the BMP-2 gene expression by MSC does not change 
when injected in animals of different ages, and in fact stimu-
lates bone formation in elderly animals. To study the repair 
of fractures, the same authors perforated the femoral bone 
then applied a porous block of calcium phosphate on the 
perforation. Before being applied on the site, this block was 
cultivated for seven days with MSCs transduced with the ade-
noviral vector (Ad5) containing the BMP-2 gene. After 6 weeks 
the MSCs expressed BMP-2. The data showed that the BMP-2 
gene restored osteogenic potential to the MSCs. The authors 
reinforce the idea that the incorporation of genetic material ex 
vivo or in vivo by means of the MSCs is a useful approach to 
the prevention or treatment of osteoporotic fractures.
Kawai et al.23 demonstrated that the plasmid transporting the 
BMP-2 gene, besides inducing endochondral ossification, 
was also able to induce intramembranous ossification in the 
gastrocnemius muscle of rats with the aid of transcutaneous 
electroporation. 
The adeno-associated,21 adenovirus,22,24 retrovirus25 and na-
ked plasmid23 vectors have already been used for the succes-
sful transfer of BMP genes. There was a positive response in 
the bone tissue in all of the above-mentioned vectors, but the 
choice of the best vector for osteoporosis treatment is still 
under discussion.
Besides the possibility of treating osteoporosis by stimulating 
bone formation, gene therapy can also act in the resorption 
mechanisms.26-28 Osteoprotegerin (OPG) is an endogenous 
protein synthesized by the osteoblasts, and is responsible for 
the inhibition of osteoclastogenesis and of osteoclast activity. 
OPG acts as an attraction to RANKL (receptor activator of 
nuclear factor-kB ligand), impairing its bond with RANK (re-
ceptor activator of nuclear factor-kB), for which reason there 
is no induction of the intracellular signals responsible for the 
differentiation, function and survival of the osteoclasts. OPG 
production is regulated by molecules that increase its syn-
thesis (IL-1a, IL-6, IL-11, IL-17, IL-18, TNF-α, TNF-ß, BMP-2, 
estrogen, calcium and vitamin D3) and others that decrease 
it (parathormone, glucocorticoids and prostaglandin E2).29
Kostenuik et al.27 managed to stabilize bone loss in the ini-
tial process of osteopenia, in the model of oophorectomized 
female mice. The authors used the adeno-associated vector 
as a transporter of the human OPG gene. The bone mineral 
density of the tibia increased significantly in the animals that 
received the OPG gene, with a reduction also in the quantity 
of osteoclasts on the surface of the proximal tibial metaphysis. 
The sham-operated mice (exposure of the ovaries, but without 
removal), also exhibited an increase of bone mineral density 
when compared with the other animals that received a gene 
without effect on the bone metabolism.
The adenovirus carrying the OPG gene was also studied 
for osteoporosis treatment. In transducing a host cell, this 
type of vector maintains the genome not integrated into 
the chromosome (episomal form), but when the infected 
cell divides the episome may get lost, which can also lead 
to an immune response, and consequently the effect of 
the therapeutic gene is lost. Nevertheless, Bolon et al.28 
demonstrated that the expression can be maintained for 
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at least 18 months and lead to an increase of bone density. 
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concluSion
Few reports in scientific literature used gene therapy as an 
instrument to treat osteoporosis.
The calcified matrix of the bone tissue represents an additio-
nal obstacle in the study of gene therapy for osteometabolic 
diseases, as the diffusion of the vector through matrix is prac-
tically impossible, which makes this therapy more elaborate 
for osteoporosis, directly affecting the success of the trans-
fection or transduction of the osteogenic cells. One alternative 
to circumvent this obstacle is related to the use of mesenchy-
mal stem cells carrying the therapeutic gene, since they are 
osteoblast precursor cells and are reflected in the increase 
of bone mass due to matrix synthesis.18,22 Nevertheless, the 
studies reported reestablished bone mass and thus reduced 
the risk of fractures.
Most studies reported the use of only one therapeutic gene. 
Theoretically, nothing prevents the plasmid expression cas-
sette from having genic sequences to act both in the osteo-
blasts, stimulating bone formation, and in the osteoclasts, 
decreasing the resorption rate. Thus is possible to potentiate 
the treatment for osteoporosis and to have a faster positive re-
sponse, particularly for individuals with severe osteoporosis.
A large portion of the studies uses OPG, BMP and PTH as 
promising molecules for osteoporosis treatment, yet there is a 
lack of new molecules as possible targets to be studied, prac-
tically limiting researchers to the use of the same molecules. 
Nonetheless, the RGD sequence and the study with human 
ß3 integrin proved to be important targets for antiresorptive 
gene therapy.16,31
Future studies should be carried out with a focus on the use 
of large animal models, the use of new therapeutic genes and 
of the best vector for gene transfer.
The cost, route of administration and side effects are some of 
the undesirable factors that may culminate in the abandon-
ment or interruption of the conventional treatment, compromis-
ing the efficacy of the medication and the patient’s health.8 In 
patient treated by gene therapy, the abandonment and/or in-
terruption of treatment is expected to become less frequent.
In the attempt to reduce negative aspects in the current thera-
peutic approach to osteoporosis, gene therapy shows itself 
to be an important tool. It is expected that in the future, by 
means of one or few minimally invasive interventions, the the-
rapeutic gene will be able to reestablish bone tissue function 
and to cause few or no side effects. For this reason, control 
of the expression level is essential, since a low level may 
not produce the therapeutic results and the inverse may be 
harmful to the cell. Control mechanisms are being studied 
to control gene expression.11,32
With the advances of genetic engineering techniques, the cost 
of this therapy should drop considerably. The benefits that 
this tool will be able to bring to patients in the future should 
contribute substantially to the increase in the prospects and 
in the quality of life of the elderly, particularly of the female 
population, which suffers most from this disease. 
The prevention or the faster reestablishment of fractures ari-
sing from osteoporosis will certainly entail a lesser economic 
impact on the government budget.5
In the near future, clinical protocols involving humans should bring 
hope to thousands of people that suffer from this disease.
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